PML is required for telomere stability in non-neoplastic human cells

Oncogene

Volumn 35, Issue 14, 2016, Pages 1811-1821

  Marchesini, M ^a,b,e   Matocci, R ^a   Tasselli, L ^a,b,f,g   Cambiaghi, V ^b   Orleth, A ^b   Furia, L ^b   Marinelli, C ^a,b   Lombardi, S ^b   Sammarelli, G ^c   Aversa, F ^c   Minucci, S ^b,d   Faretta, M ^b   Pelicci, P G ^b,d   Grignani, F ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN RETINOIC ACID RECEPTOR ALPHA FUSION PROTEIN; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; ONCOPROTEIN; PML PROTEIN, HUMAN; RARA PROTEIN, HUMAN; RARA PROTEIN, MOUSE; RETINOIC ACID RECEPTOR; TELOMERASE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CARCINOGENESIS; CELL AGING; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; FEMALE; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TELOMERE; TELOMERE SHORTENING; ANIMAL; CELL LINE; CELL PROLIFERATION; GENETICS; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; CARCINOGENESIS; CELL AGING; CELL LINE; CELL PROLIFERATION; GENOMIC INSTABILITY; HUMANS; MICE; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROMYELOCYTIC LEUKEMIA PROTEIN; RECEPTORS, RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; T-LYMPHOCYTES; TELOMERASE; TELOMERE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84933575664     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.246     Document Type: Article

References (62)

1. Akbar AN, Vukmanovic-Stejic M. Telomerase in T lymphocytes: use it and lose it? J Immunol 2007; 178: 6689-6694
2. Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE et al. DNA doublestrand break repair proteins are required to cap the ends of mammalian chromosomes. Proc Nati Acad Sci USA 1999; 96: 14899-14904
3. Nandakumar J, Cech TR. Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol 2013; 14: 69-82
4. D'adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al.A DNA damage checkpoint response in telomere-initiated senescence, Nature. 2003 426. 194-198.
5. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-1556
6. Stagno D'Alcontres M, Mendez-Bermudez A, Foxon JL, Royle NJ, Salomoni P. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA. J Cell Biol 2007; 179: 855-867
7. Karlseder J, Smogorzewska A. de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 2002; 295: 2446-2449
8. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621
9. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-460
10. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Nati Acad Sci USA 1992; 89: 10114-10118
11. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24: 2463-2479
12. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest 2013; 123: 996-1002
13. Newgard CB, Sharpless NE. Coming of age: molecular drivers of aging and therapeutic opportunities. J Clin Invest 2013; 123: 946-950
14. van Deursen JM. The role of senescent cells in ageing. Nature 2014; 509: 439-446
15. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-413
16. Flores I, Benetti R, Blasco MA. Telomerase regulation and stem cell behaviour. Curr Opin Cell Biol 2006; 18: 254-260
17. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015
18. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3: 1271-1274
19. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11: 319-330
20. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59: 4175-4179
21. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991; 6: 1285-1292
22. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684
23. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674
24. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991; 254: 1371-1374
25. de The H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 2012; 198: 11-21
26. Pearson M, Pelicci PG., PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene, 2001 20. 7250-7256.
27. Carbone R, Pearson M, Minucci S, Pelicci PG. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 2002; 21: 1633-1640
28. Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG et al. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol 2006; 175: 55-66
29. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002; 108: 165-170
30. Mazza M, Pelicci PG. Is PML a tumor suppressor? Front Oncol 2013; 3: 174
31. Slatter TL, Tan X, Yuen YC, Gunningham S, Ma SS, Daly E et al. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J Phatol 2012; 226: 509-518
32. Chang FT, McGhie JD, Chan FL, Tang MC, Anderson MA, Mann JR et al. PML bodies provide an important platform for the maintenance of telomeric chromatin integrity in embryonic stem cells. Nucleic Acids Res 2013; 41: 4447-4458
33. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561
34. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215
35. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013; 152: 390-393
36. Furia L, Pelicci PG, Faretta M. A computational platform for robotized fluorescence microscopy (I): high-content image-based cell-cycle analysis. Cytometry A 2013; 83: 333-343
37. Furia L, Pelicci PG, Faretta M. A computational platform for robotized fluorescence microscopy (II): DNA damage, replication, checkpoint activation, and cell cycle progression by high-content high-resolution multiparameter image-cytometry. Cytometry A 2013; 83: 344-355
38. Leonetti C, Amodei S, D'Angelo C, Rizzo A, Benassi B, Antonelli A et al. Biological activity of the G-quadruplex ligand RHPS4 (3, 11-difluoro-6, 8, 13-trimethyl-8Hquino[ 4, 3, 2-kl]acridinium methosulfate) is associated with telomere capping alteration. Mol Pharmacol 2004; 66: 1138-1146
39. Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest 2007; 117: 3236-3247
40. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-413
41. Fenech M, Crott JW. Micronuclei nucleoplasmic bridges and nuclear buds induced in folic acid deficient human lymphocytes-evidence for breakagefusion- bridge cycles in the cytokinesis-block micronucleus assay. Mutat Res 2002; 504: 131-136
42. Ghaffari SH, Shayan-Asl N, Jamialahmadi AH, Alimoghaddam K, Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol 2008; 19: 1927-1934
43. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002; 100: 2989-2995
44. Slatter T, Gifford-Garner J, Wiles A, Tan X, Chen YJ, MacFarlane M et al. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. Am J Pathol 2010; 177: 2694-2700
45. Verdun RE, Crabbe L, Haggblom C, Karlseder J. Functional human telomeres are recognized as DNA damage in G2 of the cell cycle. Mol Cell 2005; 20: 551-561
46. Berardinelli F, Antoccia A, Cherubini R, De Nadal V, Gerardi S, Cirrone GA et al. Transient activation of the ALT pathway in human primary fibroblasts exposed to high-LET radiation. Radiat Res 2010; 174: 539-549
47. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012; 13: 693-704
48. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 2004; 9: 963-977
49. O'Sullivan RJ, Arnoult N, Lackner DH, Oganesian L, Haggblom C, Corpet A et al. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nat Struct Mol Biol 2014; 21: 167-174
50. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818
51. Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814
52. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18: 126-135
53. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96: 314-321
54. Pantic M, Novak A, Marisavljevic D, Djordjevic V, Elezovic I, Vidovic A et al. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol 2000; 17: 307-313
55. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L et al. Cre-loxregulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-10385
56. Vian L, Di Carlo M, Pelosi E, Fazi F, Santoro S, Cerio AM et al. Transcriptional finetuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ 2014; 21: 290-301
57. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Nati Acad Sci USA 1995; 92: 9363-9367
58. Fenech M. The in vitro micronucleus technique. Mutat Res 2000; 455: 81-95
59. Gisselsson D, Bjork J, Hoglund M, Mertens F, Dal Cin P, Akerman M et al. Abnormal nuclear shape in solid tumors reflects mitotic instability. Am J Pathol 2001; 158: 199-206
60. Racanicchi S, Maccherani C, Liberatore C, Billi M, Gelmetti V, Panigada M et al. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J 2005; 24: 1232-1242
61. Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Luchetti L et al. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000; 96: 1531-1537
62. Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol 1998; 16: 743-747